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Abstract
Background—The recombination-activating gene (RAG) 1/2 proteins play a critical role in the
development of T and B cells by initiating the VDJ recombination process that leads to generation
of a broad T-cell receptor (TCR) and B-cell receptor repertoire. Pathogenic mutations in the
RAG1/2 genes result in various forms of primary immunodeficiency, ranging from T−B− severe
combined immune deficiency to delayed-onset disease with granuloma formation, autoimmunity,
or both. It is not clear what contributes to such heterogeneity of phenotypes.
Objective—We sought to investigate the molecular basis for phenotypic diversity presented in
patients with various RAG1 mutations.
Methods—We have developed a flow cytometry–based assay that allows analysis of RAG
recombination activity based on green fluorescent protein expression and have assessed the
induction of the Ighc locus rearrangements in mouse Rag1−/− pro-B cells reconstituted with wild-
type or mutant human RAG1 (hRAG1) using deep sequencing technology.
Results—Here we demonstrate correlation between defective recombination activity of hRAG1
mutant proteins and severity of the clinical and immunologic phenotype and provide insights on
the molecular mechanisms accounting for such phenotypic diversity.
Conclusions—Using a sensitive assay to measure the RAG1 activity level of 79 mutations in a
physiologic setting, we demonstrate correlation between recombination activity of RAG1 mutants
and the severity of clinical presentation and show that RAG1 mutants can induce specific
abnormalities of the VDJ recombination process.
Keywords
Recombination-activating gene 1; V(D)J recombination; severe combined immune deficiency;
Omenn syndrome; autoimmunity; genotype-phenotype correlation; immune repertoire
The recombination-activating gene (RAG) 1 and RAG2 proteins initiate the VDJ
recombination process by generating DNA double-strand breaks at the recombination signal
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sequences (RSSs) that flank the variable (V), diversity (D), and joining (J) gene segments of
the immunoglobulin and T-cell receptor (TCR) genes.1 These DNA double-strand breaks are
then joined by the ubiquitous mechanism of nonhomologous end-joining machinery.2 As a
result of VDJ recombination, a polyclonal pool of functional T and B lymphocytes is
generated, expressing a diverse repertoire of productive TCR and B-cell receptor
rearrangements.
Null mutations of RAG1 and RAG2 genes result in the T−B− severe combined immune
deficiency (SCID) phenotype.3 However, hypomorphic RAG mutations have been associated
with a spectrum of clinical and immunologic phenotypes that include Omenn syndrome
(OS),4–10 with erythroderma, lymphadenopathy, eosinophilia, increased serum IgE levels,
and the presence of autologous, oligoclonal, and activated T lymphocytes; leaky/atypical
SCID,10 with varying numbers of T and B cells but without the typical features of OS; SCID
with expansion of γδ T lymphocytes (γδ-T),11,12 which us often associated with
cytomegalovirus infection; delayed-onset combined immune deficiency with granuloma
and/or autoimmunity (CID-G/A)13–15; and in a single case of idiopathic CD4+ T cell
lymphopenia (ICL), presenting with extensive chickenpox and recurrent pneumonia.16
Attempts to correlate the phenotypic diversity of RAG-related disorders in human subjects
with functional activity of the mutant proteins were largely based on a transient transfection
assay in nonlymphoid adherent cells.17 In this assay cells are cotransfected with plasmids
encoding for wild-type (or mutant) human RAG1 (hRAG1) and hRAG2 and a third plasmid
containing a suitable recombination substrate that would allow expression of an antibiotic
resistance gene upon recognition and cleavage by hRAG1 and hRAG2 and nonhomologous
end joining–mediated ligation. However, with this assay, the recombination activity of RAG
proteins is analyzed on an extrachromosomal substrate (ie, a nonphysiologic setting), and
functional impairment of mutants that specifically affect nuclear translocation of the hRAG
proteins might be missed. Furthermore, it has been shown that stability and posttranslational
modifications of the RAG proteins differ significantly in lymphoid versus nonlymphoid
cells.18
Recently, Abelson murine leukemia virus (A-MuLV)– transformed pro-B cells containing
an inverted green fluorescent protein (GFP) cassette flanked by RSS (pMX-INV) have been
used to measure VDJ recombination activity on an intrachromosomal substrate by using
flow cytometry with GFP expression as a read-out.19 On the basis of this platform, we have
analyzed the expression and recombination activity of 79 naturally occurring hRAG1 mutant
proteins and thereby performed the largest comprehensive analysis of genotype-proteotype-
phenotype correlation for hRAG1 deficiency. Our results provide novel insights into the
molecular mechanisms underlying phenotypic diversity in patients with this disease.
METHODS
Patient selection and assignment to phenotypic subgroups
Deidentified patients’ clinical, immunologic, and molecular data were provided by an
international network of physicians in Europe, the Middle East, South America, and the
United States, according to protocols approved by the local institutional review boards. On
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the basis of phenotype, each patient was assigned to one of the following subgroups: T−B−
SCID, OS, γδ-T, atypical/leaky SCID-G/A, and ICL.
Determination of recombinase activity level of wild-type and mutant RAG1
Analysis of recombination activity of wild-type and mutant RAG1 constructs was
performed, as previously described.14 For detailed methods, see the Methods section in this
article’s Online Repository at www.jacionline.org.
Immune repertoire analysis—Analysis of rearrangements at the endogenous Ighc locus
was performed by using as a template the mRNA extracted from A-MuLV pro-B cells
transduced with retroviral vectors encoding for wild-type or mutant hRAG1. A set of nested
primers specific for various VH and CH elements of the Ighc locus were used for the first
amplification cycles, followed by amplification with communal primers according to the
manufacturer’s protocol for MBCR (iRepertoire, Huntsville, Ala). By using this protocol,
ampliconrescued multiplex PCR allows semiquantitative amplification of the immune
repertoire.20 Purified PCR products were sequenced with the GS Junior 454 platform
(Roche, Mannheim, Germany).
Raw sequences were filtered for PCR errors, and a tree map and 2-dimensional map were
generated from the total complementarity-determining region (CDR)–H3 sequences to
analyze VH-JH pairing and the relative distribution of distinct rearrangements (iRepertoire).
The filtered sequences, excluding duplicates, were further analyzed for VH, DH, and JH gene
usage; composition; CDR-H3 length; reading frame (RF) determination; and the diversity
index of Shannon entropy by using IMGT HighV-QUEST output files21 and IgAT
software.22 Rarefaction curves were generated by using the VDJ statistics file from IgAT
analysis and the PAST program.23 To assess reproducibility, 2 runs on independent
amplification libraries were performed for R699Q, and 2 to 3 repeats of the same
amplification library were run for the R314W and M435V mutants.
Statistical analysis—Results of recombination activity of hRAG1 proteins were analyzed
with the Mann-Whitney U test. The χ2 test was used to assess skewing in the use of VH,
DH, and JH genes by various hRAG1 mutant proteins compared with wild-type hRAG1. The
unpaired 2-tailed t test was used to analyze the average CDR-H3 length, the average index
of hydrophobicity according to a normalized Kyte-Doolittle scale, differential use of 3 RFs,
and the average Shannon entropy of the CDR-H3 loop. Nonparametric Spearman correlation
was used to determine correlation between the recombination activity level and protein
expression of various hRAG1 mutants by using the Spearman correlation coefficient (rs).
RESULTS
Recombination activity and protein expression of hRAG1 mutants
We have compiled a list of 79 distinct, naturally occurring hRAG1 genetic variants,
including 3 known polymorphisms (G99S, H249R, and K820R) and 76 distinct mutations
identified in 68 patients (among which were 34 novel cases, Table I).4–9,11–16,24–28 To
investigate correlation between the expression and function of mutant hRAG1 and the
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patients’ clinical and immunologic phenotypes, we used A-MuLV– transformed Rag1−/−
tg.Eμ-bcl2 pro-B cells (hereafter referred to as Rag1−/− Abl pro-B cells), containing a single
integration of the pMX-INV GFP cassette flanked by RSSs (Fig 1, A, and see Fig E1 in this
article’s Online Repository at www.jacionline.org),21 which were further transduced with
retroviral vectors encoding wild-type or mutant hRAG1 or wild-type mouse Rag1 (mRag1)
and hCD2 as a reporter. To control for expression of wild-type and mutant RAG1 proteins,
Rag1−/− Abl pro-B cells expressing either wild-type or mutant hRAG1 were equally
enriched to contain greater than 90% cells expressing the hCD2 reporter. Comparable levels
of GFP expression were observed on induction of wild-type hRAG1 and mRag1 expression
with STI-571 (imatinib; Fig 1, B). This treatment arrests cells in the G0/G1 phase of the cell
cycle while RAG proteins are expressed.29 We then measured the VDJ recombination
activity of 79 different naturally occurring hRAG1 variants by normalizing GFP expression
to that observed in the presence of wild-type hRAG1 (Fig 1, C, and see Table E1 in this
article’s Online Repository at www.jacionline.org). Wild-type levels of VDJ recombination
activity were observed for 3 known hRAG1 polymorphisms (G99S, H249R, and K820R)
and for N106K, R449K, R474C, H612R, A868V, and M1006V mutants, suggesting that the
latter represent neutral variants and not disease-causing mutations.
We investigated whether the specific location of RAG1 mutations might impinge on
recombination activity. Fig 2, A, shows the location of the mutations analyzed in this study
along the length of the hRAG1 protein; different colors were used to indicate the diverse
clinical and immunologic phenotypes. For mutations associated with more than 1 phenotype,
the color code corresponds to the least severe phenotype under the assumption that the
mutation is potentially permissive for some V(D)J recombination activity. We observed a
relative overrepresentation of mutations affecting the nonamer-binding region (NBR) of
hRAG1 (Fig 2, B). Moreover, missense mutations in the NBR and in the heptamer-binding
region (HBR) had a significantly lower activity level than mutations in other regions of the
RAG1 protein (Fig 2, C), which is consistent with the critical roles played by the NBR and
HBR domains in DNA recognition and binding.1 In contrast, mutations at the C-terminus of
RAG1 and some missense mutations in the central region of the molecule showed
significant residual VDJ recombination activity (Fig 2, B). These mutations have been
identified mostly in patients with CID-G/A (ie, a less severe and often delayed-onset form of
the disease), suggesting that mutations in the C-terminus of RAG1 are more tolerable than
mutations in the NBR/HBR.
Next, we analyzed correlation between recombination activity of hRAG1 mutant proteins
and the patients’ clinical and immunologic phenotype (Fig 2, D). Recombination activity of
those hRAG1 mutants that had been identified in patients belonging to various clinical
subgroups were reported for each of the subgroups to avoid a bias in the statistical analysis
of the data. VDJ recombination activity levels were greater for RAG1 mutations identified in
patients with CID-G/A and were progressively lower in patients with more severe
phenotypes, being extremely low for patients belonging to the T−B− SCID subgroup (Fig 2,
D). Furthermore, significantly lower VDJ recombination activities of hRAG1 mutants were
observed in patients with very low to absent circulating B cells (Fig 2, E). Altogether, these
data indicate that there is a strong, although imperfect, correlation between the VDJ
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recombination activity of mutant hRAG1 proteins and the associated clinical and
immunologic phenotype.
To determine whether differences in recombination activity of hRAG1 mutants might reflect
different levels of protein expression, we performed Western blotting analysis of 41 RAG1
mutants introduced into Rag1−/− Abl pro-B cells. The same amount of cells (400,000 cells),
of which greater than 90% expressed hCD2, were loaded in each lane, and adjusted RAG1
expression was calculated by using the loading control as a reference. Of 27 hRAG1 mutants
in the NBR/HBR that were studied, 13 showed very low levels of protein expression
(adjusted expression, <0.2; Fig 3, A and B). Variable levels of protein expression were
observed for NBR mutants with different amino acid substitutions at the same codon (R394
and R396; Fig 3, A), yet all of them showed very low to undetectable VDJ recombination
activity (see Table E1). Among 15 missense mutations located outside of NBR/HBR
domains, 4 had very low levels of protein expression, and 7 had expression levels
comparable with those of wild-type hRAG1 (Fig 3, C). Overall, levels of protein expression
of hRAG1 mutants affecting the NBR/HBR regions were not significantly different than
those of mutants affecting other domains (Fig 3, D). Furthermore, we observed only a
modest correlation between RAG1 mutant protein expression and recombination activity
(Fig 3, E).
Comparison of recombination activity and predicted pathogenicity of hRAG1 mutants
Bioinformatics tools might help predict the pathogenicity of DNA variants and missense
mutations in particular. To predict the pathogenicity of 63 hRAG1 missense variants, we
used the Pathogenic Or Not Pipeline (PON-P), which integrates information provided by
Phd-SNP, SNAP, PolyPhen-2, SIFT, and I-Mutant predictors into a single consensus
prediction with a reliability score.30 PON-P assigned each hRAG1 variant to a specific class
according to probability and reliability scores (P, pathogenic; N, neutral; and UV,
unclassified variant). Most variants in class P had absent or negligible recombination
activity, whereas most variants in class N had wild-type recombination activity (see Table
E1). Overall, correlation between predicted pathogenicity and in vitro recombination activity
was not perfect. However, among missense mutations located in the NBR, those affecting
residues that are directly involved in DNA binding31 were assigned to class P by using
PON-P, and they all showed absent or markedly decreased recombination activity (see Fig
E2 in this article’s Online Repository at www.jacionline.org). In contrast, missense
mutations in the more distal α-helix of the NBR, affecting residues that are not directly
involved in DNA binding, were mostly assigned to class UV and had low but detectable
recombination activity. Therefore PON-P can be informative in validating experimental
results and predicting mutations in regions with distinct and imperative activities.
Analysis of rearrangements at the endogenous Ighc locus
Introduction of hRAG1 mutants into Rag1−/− Abl pro-B cells offers the opportunity to
analyze VDJ recombination activity in a physiologic setting through the study of
rearrangements at the endogenous Ighc locus. For this purpose, we used a semiquantitative
deep-sequencing approach based on amplification of mRNA transcripts by using VH
forward primers and CH reverse primers with a communal barcode (provided by iRepertoire)
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and use of the Roche 454 pyrosequencing platform. In particular, we tested the frequency,
quality, and diversity of Ighc rearrangements induced by transduction of Rag1−/− Abl pro-B
cells with retroviral vectors encoding either wild-type hRAG1 or mRag1 or 10 distinct
hRAG1 mutants (K86Vfs33X, R142X, R314W, C328Y, M435V, G516A, R699Q, R841W,
Y912C, and K992E). These mutants were selected because they occur in different domains
of the protein, support different levels of VDJ recombination activity (as assessed based on
GFP expression), and were identified in patients representative of the phenotypic spectrum
of the disease. The total number of reads, as well as total and unique CDR-H3 sequences,
were comparable between mRag1, hRAG1, and R699Q, whereas a reduced number of reads
or no reads were obtained for all other mutants with lower activity levels than R699Q (see
Table E2 in this article’s Online Repository at www.jacionline.org).
To assess whether we had collected a sufficient number of reads to cover the diversity of
rearrangements induced by each mutant, we analyzed individual rarefaction curves in which
the number of species (VDJ rearrangement products) is plotted as a function of the number
of sequences obtained, thereby informing on the richness of the reads (see Fig E3, A, in this
article’s Online Repository at www.jacionline.org). Although a very low number of reads
was obtained for both the R314W and K992E mutants, the rarefaction curves for these
mutants were flatter than for wild-type hRAG and for other mutations of the same sample
size, indicating that an increase in sequence reads for R314W and K992E samples would not
result in a significant increase in the number of diverse VDJ recombination products (see
Fig E3, B). Furthermore, analysis of individual VH to JH pairing demonstrated progressive
restriction of the Ighc rearrangement repertoire when moving from hRAG1 mutants with
high to those with low VDJ recombination activity (Fig 4, A–F).
As expected,18,32 introduction of wild-type hRAG1 or mRag1 into Rag1−/− Abl pro-B cells
induced Ighc rearrangements that often use the most proximal VH gene segment Ighv5-2
(see Fig E4 in this article’s Online Repository at www.jacionline. org). In addition to
preferential use of this VH gene segment, skewing in the use of individual VH, DH, and JH
genes was observed for all mutants tested and especially for the R314W and K992E mutants
(Fig 4, G–I, and see Fig E5 in this article’s Online Repository at www.jacionline.org) and
for DH use (Fig 4, H, and see Fig E5, C).
Differences in the composition and length of the CDR-H3 region might affect the ability of
immunoglobulins to bind to antigens. Dynamic changes in CDR-H3 composition occur
during differentiation from pro-B to mature B cells.33 In particular, immature B cells
enriched for self-reactive specificities tend to have longer CDR-H3 sequences with presence
of positively charged amino acid residues.34,35 Because immune dysregulation is a common
feature in patients with hypomorphic RAG mutations, we sought to determine whether
introduction of these mutants into Rag1−/− Abl pro-B cells induces expression of CDR-H3
sequences that differ in length and composition from those induced by wild-type hRAG1.
There was a slight but significant increase in the length of CDR-H3 for both the R699Q
(35.24 ± 8.76 nt) and G516A (35.34 ± 8.54 nt) mutants compared with hRAG1 (34.24 ±
8.76 nt; P < .0001 and P = .0007, respectively; Fig 4, J), mainly because of a longer DH
gene segment (see Fig E6, A and B, in this article’s Online Repository at www.
jacionline.org). However, the more severe K992E mutant, which is associated with OS,
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supported generation of Ighc rearrangements characterized by markedly shorter CDR-H3
sequence (26.57 ± 8.64 nt, P = .0055; Fig 4, J). A reduced number of N nucleotide additions
at the VDJ recombination junctions (see Fig E6, A and C), a higher frequency of direct VH-
to-JH rearrangements (see Fig E6, D), a significant decrease in the average DH length (see
Fig E6, B), and a higher frequency of use of the shorter JH3 gene segment (Fig 4, I, and see
Fig E5, D) all contributed to the shorter CDR-H3 sequences, likely reflecting the impaired
function and abnormal VDJ recombination activity of the K992E mutant.
For the R699Q, G516A, and M435V mutants with higher levels of recombination activity,
the average index of CDR-H3 hydrophobicity according to Kyte-Doolittle did not deviate
much from neutral to slightly hydrophilic, which is similar to what was observed for wild-
type hRAG1 (Fig 4, K).33 In contrast, a significant shift toward a charged/hydrophilic profile
of CDR-H3 sequences was observed for the more severe R314W and K992E mutants (Fig 4,
K), mainly because of abundance of arginine, asparagine, and aspartic acid residues (see Fig
E7 in this article’s Online Repository at www.jacionline.org). The higher frequency of these
amino acids resulted mainly from N1 additions in the case of the R314W mutant and from
N2 additions for the K992E mutant (see Fig E8 in this article’s Online Repository at
www.jacionline.org). Moreover, the nature of the RF, which is largely determined by DH
genes, also contributed to the skewed use of these amino acids. In particular, the R314W
mutant induced preferential use of the neutrally charged RF1 and reduced use of the
hydrophobic RF2, whereas the K992E mutant induced more abundant use of the hydrophilic
RF3 (Fig 4, L).
Finally, to analyze the diversity of amino acid composition at each residue of the CDR-H3,
we used the Shannon entropy index (H), a measure of variability in which the higher the
score, the more variable the amino acid use at each position. The CDR-H3 diversity was
significantly reduced for the M435V, R314W, and K922E mutants but was only modestly
decreased for R699Q and G516A mutants (Fig 4, M). Homozygosity for the K992E
mutation in human subjects is associated with OS, whereas the R699Q and G516A
mutations have been identified only in patients with CID-G/A (Table I). Altogether, these
data indicate that restricted diversity in the immune repertoire correlates with severity of
impairment of RAG1 function.
DISCUSSION
An important property of the Rag1−/− Abl pro–B-cell system described here is that it allows
in-depth analysis of VDJ recombination activity at the endogenous Ighc locus before
selection processes. As expected for pro-B cells, we observed that DH1 and DH4 (commonly
known as DFL16 and DQ52, respectively) genes were preferentially targeted for
rearrangement.36 Furthermore, significant skewing toward DH4 gene use was observed with
the more severe K992E mutant, which reflects impairment of secondary D-replacement
rearrangements.
Similarly, the most DH-proximal VH2 and VH5 genes were preferentially targeted in VH-
DJH rearrangements, as also seen early during B-cell ontogeny.18,32 Even for these genes, a
skewed use by various hRAG1 mutants was observed. Moreover, increased targeting was
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observed for the other DH-proximal VH11 and VH14 genes. Although the association of
individual hRAG1 mutations with preferential targeting of specificVH genes has not been
previously reported, significantly reduced DH-JH rearrangement in mice homozygous for a
hypomorphic Rag1 mutation had been demonstrated.37 In addition, introduction of an OS-
associated mutation into themRag1 gene induced selective impairment in the ability to target
certain coding flanks at VH, DH and JH gene segments.38 Along with our findings, these data
suggest that reduced RAG1 activity might directly alter the quality of endogenous VDJ
rearrangements. Overall, hRAG1 mutants with lower recombination activity preferentially
targeted the most proximal DH elements, whereas hRAG1 mutants with relatively higher
recombination activity showed the ability to target DH distal VH gene segments, thereby
allowing generation of a more diverse repertoire. This correlated with a milder clinical and
immunologic phenotype in vivo, with preservation of B-cell development and detectable
immunoglobulin levels.
Immune dysregulation is being increasingly recognized as an important clinical phenotype
associated with hypomorphic RAG1 mutations (Table I).13–15 The R699Q and G516A
mutants induced rearrangements with longer CDR-H3 sequences, a feature that has been
previously identified in self-reactive B cells.34,35,39 These data suggest that some hRAG1
mutations might favor generation of a self-reactive B-cell repertoire by skewing the quality
of VDJ rearrangements. On the other hand, generation of markedly shorter CDR-H3
sequences caused by increased use of the stop codon–rich RF3 has been observed for the
K992E mutant identified in 2 patients with OS.
One caveat of the Rag1−/− Abl pro–B-cell system described here is that it allows in-depth
analysis of the recombination properties of one mutant at a time. In contrast, many patients
carry compound heterozygous mutations. Use of polycistronic vectors might allow analysis
of the combined effect of 2 distinct mutations.
In conclusion, this study represents the most comprehensive study of the expression and
function of hRAG1 mutants identified in patients with a spectrum of clinical and
immunologic presentations. Using this platform, we have demonstrated genotype-phenotype
correlation and have provided novel molecular insights that might help explain the
phenotypic diversity of this disease. The results presented in this study could serve as a
reference for recombination activity of known RAG1 variants. Moreover, the fluorescence-
activated cell sorting–based assay described here could represent a helpful cellular platform
to assess the pathogenicity of newly identified RAG1 variants. This would be especially
important in the diagnostic approach to asymptomatic or presymptomatic subjects with
RAG1 mutations, including those identified at birth through newborn screening. Note added
in proofs: Yu et al40 have recently demonstrated restricted TCRβ diversity in patients with
OS, and preserved diversity, but skewed usage of V, D and J elements in patients with CID-
G/A.
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Key messages
• We describe a cellular platform that permits rapid analysis of expression and
recombination activity of RAG1 mutant variants.
• RAG1 recombination activity correlates with the severity of the clinical and
immunologic phenotype observed in vivo.
• Mutant RAG1 proteins differ in the efficiency and quality of V(D)J
recombination activity, indicating that skewing of the immune repertoire might
occur independently from in vivo selection.
Lee et al. Page 14
J Allergy Clin Immunol. Author manuscript; available in PMC 2015 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
FIG 1.
Schematic representation of the experimental outline and readout. A, A mouse Abelson (Abl) virus–transformed pro–B-cell line
deficient for mRag1 was infected with a retrovirus containing an inverted GFP cassette. Subclones with single-copy stable
integrants were transduced with vectors expressing wild-type RAG1 or various hRAG1 mutations (see Table E1) and then treated
with imatinib to promote cell differentiation and induction of RAG1 activity.21 B and C, The level of GFP expression indicated
the recombinase activity level on imatinib stimulation of Rag1−/− Abl pro-B cells transduced with an empty vector, or with
vectors encoding either for wild-type hRAG1 (hWT) or wild-type mRag1 (mWT; Fig 1, B) or for one representative hRAG1
mutation for each of the 5 different phenotypic subgroups of the disease (Fig 1, C). LTR, Long terminal repeats.
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FIG 2.
Activity levels of 79 genetic variants of hRAG1. A, Schematic representation of 79 genetic variants of hRAG1 affecting the
various domains: RING, zinc finger RING type domain (amino acids 168–283); ZFA, zinc finger A; NBR (amino acids 387–
461); HBR (amino acids 531–763); ZFB, zinc finger B; and the core domain from amino acids 385 to 1011. The conserved
cysteine (C) and histidine (H) residues are marked with black lines, and the basic domains are marked with bars. They are as
follows: C1 (103/115); C2 (169/181); C3 (204/214) CH (269/275); CC (905/910); HH (940/945); BI (142–147); BIIa (219–
225); BIIb (234–237); and BIII (244–257). The RAG1 variants are color coded, corresponding to the clinical phenotype of
patients in which they were identified (red = T−/B− SCID, orange = OS, green = γδ-T, blue = atypical/leaky SCID, and purple
= CID-G/A). The asterisk marks mutations associated with other phenotypes. Mutations in black correspond to alleles with the
lower recombination activity that had been identified in patients who were compound heterozygous for RAG1 mutations. Known
polymorphisms are indicated in pink, and gray is used to identify variants detected in patients for whom incomplete clinical and
immunologic information was available. B, Bar diagram representing the activity level of various hRAG1 mutants relative to
wild-type hRAG1. Values are expressed as percentages ± SEMs. For each mutant, 3 to 5 independent experiments were
performed. Mutations falling in the NBR and HBR are contained in shaded areas. C, Recombination activity of missense
mutations falling in the NBR/HBR versus other regions of hRAG1. D, Recombination activity of hRAG1 mutants identified in
patients with a distinct clinical and immunologic phenotype. E, Recombination activity of hRAG1 mutants identified in patients
with virtual lack of circulating B cells (<30 cells/µL) and in those with residual B cells (≥30 cells/µL). The Mann-Whitney U
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test was performed to demonstrate statistical significance for all the 1-tailed P values in the graphs: **P < .01, ***P < .001, and
****P < .0001.
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FIG 3.
Protein expression of hRAG1 mutants. A–C, Protein expression of hRAG1 mutants affecting NBR (Fig 3, A), HBR (Fig 3, B),
and non-NBR/HBR (Fig 3, C) domains. Expression of β-actin was used to normalize the density for each of the hRAG1 mutants.
Results are shown as adjusted density (ImageJ). One representative of 2 immunoblots is shown. D, Adjusted density of hRAG1
protein expression of mutants affecting the NBR/HBR or non-NBR/HBR domains of the molecule. ns, Not significant.
Statistical analysis was performed with the Mann-Whitney U test. E, Correlation between adjusted density of protein expression
and recombination activity of RAG1 mutants (Spearman rs = 0.351, P = .023).
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FIG 4.
Diversity and CDR-H3 characteristics and composition of the rearranged Ighc repertoire of hRAG1 mutations. A–F, Tree maps
(iRepertoire) were generated to depict graphically the diversity and frequency of different V–J pairings induced by various
hRAG1 mutants: wild-type hRAG1 (Fig 4, A); R699Q (Fig 4, B); G516A (Fig 4, C); M435V (Fig 4, D); R314W (Fig 4, E); and
K992E (Fig 4, F). Each dot represents a unique VH-JH recombination, and the size of the dot indicates the relative frequency of
that specific V-JH rearrangement. G–I, Bar diagrams representing the uses of VH (Fig 4, G), DH (Fig 4, H), and JH (Fig 4, I)
genes for wild-type hRAG1 and various hRAG1 mutants. For the VH genes, only the genes that had positive values are included.
J–M, Characterization of CDR-H3 sequences: average CDR-H3 length (± SEM; Fig 4, J); average index of hydrophobicity (±
SEM) according to a normalized Kyte-Doolittle scale (Fig 4, K); differential use of 3 RFs (Fig 4, L); and average Shannon
entropy index (± SEM) of the CDR-H3 loop (Fig 4, M). *P < .05, **P < .01, ***P < .001, and ****P < .0001 unpaired 2-tailed t
test.
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